Christopher G. Azzoli

14.9k total citations · 7 hit papers
154 papers, 10.2k citations indexed

About

Christopher G. Azzoli is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Christopher G. Azzoli has authored 154 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Pulmonary and Respiratory Medicine, 107 papers in Oncology and 38 papers in Molecular Biology. Recurrent topics in Christopher G. Azzoli's work include Lung Cancer Treatments and Mutations (100 papers), Lung Cancer Research Studies (54 papers) and Lung Cancer Diagnosis and Treatment (51 papers). Christopher G. Azzoli is often cited by papers focused on Lung Cancer Treatments and Mutations (100 papers), Lung Cancer Research Studies (54 papers) and Lung Cancer Diagnosis and Treatment (51 papers). Christopher G. Azzoli collaborates with scholars based in United States, Australia and Japan. Christopher G. Azzoli's co-authors include Mark G. Kris, John R. Strawn, William Pao, Sherman Baker, Thomas J. Smith, Vincent A. Miller, Lee M. Krug, Naiyer A. Rizvi, David G. Pfister and Sarah Temin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Journal of Clinical Oncology.

In The Last Decade

Christopher G. Azzoli

150 papers receiving 10.0k citations

Hit Papers

American Society of Clinical Oncology Treatment of Unrese... 2003 2026 2010 2018 2003 2012 2009 2015 2004 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
    2003 1.2k citations David G. Pfister, David H. Johnson et al. Journal of Clinical Oncology profile →
  2. Benefits and Harms of CT Screening for Lung Cancer
    2012 927 citations Christopher G. Azzoli et al. profile →
  3. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
    2009 752 citations Christopher G. Azzoli, Sherman Baker et al. Journal of Clinical Oncology profile →
  4. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2015 695 citations Gregory A. Masters, Sarah Temin et al. Journal of Clinical Oncology profile →
  5. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
    2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
  6. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update
    2017 235 citations Mark G. Kris, Jamie E. Chaft et al. Journal of Clinical Oncology profile →
  7. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
    2021 222 citations Jamie E. Chaft, Andreas Rimner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher G. Azzoli United States 49 7.5k 6.0k 2.4k 1.4k 1.1k 154 10.2k
Edward S. Kim United States 52 5.3k 0.7× 5.2k 0.9× 2.9k 1.2× 1.9k 1.3× 665 0.6× 216 9.8k
Frank V. Fossella United States 47 9.1k 1.2× 8.6k 1.4× 2.5k 1.0× 1.1k 0.7× 833 0.8× 197 12.8k
Maciej Krzakowski Poland 43 6.4k 0.9× 7.6k 1.3× 2.2k 0.9× 1.6k 1.1× 785 0.7× 261 11.4k
Rafał Dziadziuszko Poland 44 6.3k 0.8× 5.8k 1.0× 2.7k 1.1× 1.8k 1.3× 440 0.4× 290 9.0k
Wilfried Eberhardt Germany 39 5.3k 0.7× 4.2k 0.7× 1.7k 0.7× 892 0.6× 895 0.8× 239 7.6k
Christian Manegold Germany 39 13.0k 1.7× 9.4k 1.6× 3.2k 1.3× 1.9k 1.3× 1.1k 1.1× 113 16.2k
Marcello Tiseo Italy 49 5.4k 0.7× 5.1k 0.9× 2.8k 1.2× 1.4k 1.0× 479 0.4× 373 8.5k
Roberto Bianco Italy 49 3.4k 0.5× 5.0k 0.8× 3.7k 1.5× 1.2k 0.9× 898 0.8× 208 8.9k
Gregory P. Kalemkerian United States 45 3.9k 0.5× 3.9k 0.7× 2.3k 0.9× 1.2k 0.8× 1.1k 1.0× 179 7.8k
Baohui Han China 42 4.6k 0.6× 3.9k 0.7× 1.9k 0.8× 1.4k 1.0× 510 0.5× 458 7.7k

Countries citing papers authored by Christopher G. Azzoli

Since Specialization
Citations

This map shows the geographic impact of Christopher G. Azzoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher G. Azzoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher G. Azzoli more than expected).

Fields of papers citing papers by Christopher G. Azzoli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher G. Azzoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher G. Azzoli. The network helps show where Christopher G. Azzoli may publish in the future.

Co-authorship network of co-authors of Christopher G. Azzoli

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher G. Azzoli. A scholar is included among the top collaborators of Christopher G. Azzoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher G. Azzoli. Christopher G. Azzoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pennell, Nathan A., Joel W. Neal, Jamie E. Chaft, et al.. (2018). SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 37(2). 97–104. 137 indexed citations
2.
Azzoli, Christopher G., et al.. (2016). Bilateral acute simultaneous onset anterior uveitis presumed secondary to erlotinib: A report of two cases. American Journal of Ophthalmology Case Reports. 6. 21–23. 4 indexed citations
3.
Li, Bob T., Emil Lou, Meier Hsu, et al.. (2016). Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. PLoS ONE. 11(1). e0146063–e0146063. 18 indexed citations
4.
Li, Bob T., Alexander Drilon, Melissa L. Johnson, et al.. (2015). A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers. Annals of Oncology. 27(1). 154–159. 44 indexed citations
5.
Chaft, Jamie E., Anya M. Litvak, Maria E. Arcila, et al.. (2014). Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation. Clinical Lung Cancer. 15(6). 405–410. 64 indexed citations
6.
Willers, Henning, Christopher G. Azzoli, Wil L. Santivasi, & Fen Xia. (2013). Basic Mechanisms of Therapeutic Resistance to Radiation and Chemotherapy in Lung Cancer. The Cancer Journal. 19(3). 200–207. 176 indexed citations
7.
8.
Pietanza, M. Catherine, Kyuichi Kadota, Kety Huberman, et al.. (2012). Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker. Clinical Cancer Research. 18(4). 1138–1145. 122 indexed citations
9.
Oxnard, Geoffrey R., Vincent A. Miller, Mark E. Robson, et al.. (2012). Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping. Journal of Thoracic Oncology. 7(6). 1049–1052. 99 indexed citations
10.
Oxnard, Geoffrey R., Yelena Y. Janjigian, Maria E. Arcila, et al.. (2011). Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib. Clinical Cancer Research. 17(19). 6322–6328. 50 indexed citations
11.
D’Angelo, Sandra P., Mark G. Kris, M. Catherine Pietanza, Naiyer A. Rizvi, & Christopher G. Azzoli. (2011). A Case Series of Dose-Limiting Peripheral Edema Observed in Patients Treated with Pemetrexed. Journal of Thoracic Oncology. 6(3). 624–626. 13 indexed citations
12.
Johnson, Melissa L., Greg J. Riely, Naiyer A. Rizvi, et al.. (2011). Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib. Journal of Thoracic Oncology. 6(6). 1128–1131. 68 indexed citations
13.
Girard, Nicolas, Emil Lou, Christopher G. Azzoli, et al.. (2010). Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report. Clinical Cancer Research. 16(2). 755–763. 70 indexed citations
14.
Janjigian, Yelena Y., Bernard J. Park, Maureen F. Zakowski, et al.. (2010). Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations. Journal of Thoracic Oncology. 6(3). 569–575. 101 indexed citations
15.
Price, Katharine A., Christopher G. Azzoli, Lee M. Krug, et al.. (2010). Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(10). 1623–1629. 74 indexed citations
16.
Azzoli, Christopher G., Sherman Baker, Sarah Temin, et al.. (2009). American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27(36). 6251–6266. 752 indexed citations breakdown →
17.
Marks, Jenifer L., Stephen Broderick, Qin Zhou, et al.. (2008). Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma. Journal of Thoracic Oncology. 3(2). 111–116. 202 indexed citations
18.
James, Leonard P., Christopher G. Azzoli, Lee M. Krug, et al.. (2007). Phase I study of the anitfolate pralatrexate given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC). Molecular Cancer Therapeutics. 6. 1 indexed citations
19.
Azzoli, Christopher G., Lee M. Krug, Vincent A. Miller, et al.. (2007). A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(7). 638–644. 11 indexed citations
20.
Herbst, Roy S., Rafat Ansari, В. А. Горбунова, et al.. (2007). B1-06: Multicenter, randomized study of Docetaxel versus Docetaxel plus Oblimersen in patients previously treated for non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S335–S335. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edward S. Kim Breakdown of academic impact, for papers by Frank V. Fossella Breakdown of academic impact, for papers by Maciej Krzakowski Breakdown of academic impact, for papers by Rafał Dziadziuszko Breakdown of academic impact, for papers by Wilfried Eberhardt Breakdown of academic impact, for papers by Christian Manegold Breakdown of academic impact, for papers by Marcello Tiseo Breakdown of academic impact, for papers by Roberto Bianco Breakdown of academic impact, for papers by Gregory P. Kalemkerian Breakdown of academic impact, for papers by Baohui Han
Rankless by CCL
2026